During radiotherapy, immune-modulatory effects of radiation doses should be taken into consideration, not only the anti-tumor radiation effects. Thus, our study aimed to study how γ-radiation modulates immune response in comparison to common immune-suppressive/stimulant agents. Animals were divided into two groups. received Echinacea purpura extract (EP) or irradiated at low radiation doses 0, .25 or .5 Gray (Gy), whereas received cyclophosphamide (CP) or irradiated at high radiation doses 1, 2, or 5 Gy. Serum levels of immunological mediators interleukin-10 (IL-10) and tumor necrosis factor (TNF-α), as well as redox-markers malondialdehyde (MDA) and nitric oxide (NO), hemoglobin (Hgb), white and red blood cells (WBCs, RBCs), and platelet counts were assessed following irradiation. Of the immune-stimulant category, .25 Gy dose offered EP-comparable effects in TNF-α, RBCs, Hgb, and platelet counts cases. As for the immune-suppressive category; 5 Gy irradiation dose induced inflammatory/immunosuppressive responses indicated (rise in NO, TNF-α, and IL-10), and an oxidative stress status (increase in serum MDA). However, 5 Gy γ-irradiation was not observed, herein, as a single immunosuppressive agent. To conclude, during radiotherapy, immunological impact(s) of the used radiation doses should be optimized and followed-up closely to assess the risk/benefit of their usage.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288439 | PMC |
http://dx.doi.org/10.1177/15593258231185461 | DOI Listing |
Cureus
December 2024
Radiation Oncology, Thomas Jefferson University Hospital, Philadelphia, USA.
Purpose Low-dose total skin electron beam therapy (LD-TSEBT) has recently gained popularity in treating mycosis fungoides (MF) due to its reduced toxicity and favorable response rates. Combining accelerated LD-TSEBT with the modified Stanford technique (mST), a condensed cycling approach, offers a promising and convenient option. However, in vivo dosimetry data confirming the effectiveness of this approach is limited.
View Article and Find Full Text PDFIndian J Nucl Med
November 2024
Department of Nuclear Medicine and Molecular Imaging, Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Mumbai, Maharashtra, India.
Objective: Lu-DOTATATE peptide receptor therapy (PRRT) is an established treatment for patients suffering from neuroendocrine tumors. In the last few years, intra-arterial PRRT is being considered for patients having liver metastatic disease predominantly. The aim of our study is to measure the radiation doses received by the treating intervention radiologists involved in intra-arterial PRRT treatment using Lu-DOTATATE.
View Article and Find Full Text PDFClin Transl Radiat Oncol
March 2025
Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
Purpose: To use imaging data from stereotactic MR-guided online adaptive radiotherapy (SMART) of ultracentral lung tumors (ULT) for development of a safe non-adaptive approach towards stereotactic body radiotherapy (SBRT) of ULT.
Patients And Methods: Analysis is based on 19 patients with ULT who received SMART (10 × 5.0-5.
J Neuroimaging
January 2025
Toulouse NeuroImaging Center (ToNIC), INSERM, University of Toulouse Paul Sabatier, Toulouse, France.
Background And Purpose: Working memory, a primary cognitive domain, is often impaired in pediatric brain tumor survivors, affecting their attention and processing speed. This study investigated the long-term effects of treatments, including surgery, radiotherapy (RT), and chemotherapy (CT), on working memory tracts in children with posterior fossa tumors (PFTs) using resting-state functional MRI (rs-fMRI) and diffusion MRI tractography.
Methods: This study included 16 medulloblastoma (MB) survivors treated with postoperative RT and CT, 14 pilocytic astrocytoma (PA) survivors treated with surgery alone, and 16 healthy controls from the Imaging Memory after Pediatric Cancer in children, adolescents, and young adults study (NCT04324450).
Med Phys
January 2025
Department of Radiation Oncology, Inha University Hospital, Incheon, Republic of Korea.
Background: High-dose-rate (HDR) brachytherapy using Iridium-192 as a radiation source is widely employed in cancer treatment to deliver concentrated radiation doses while minimizing normal tissue exposure. In this treatment, the precision with which the sealed radioisotope source is delivered significantly impacts clinical outcomes.
Purpose: This study aims to evaluate the feasibility of a new four-dimensional (4D) in vivo source tracking and treatment verification system for HDR brachytherapy using a patient-specific approach.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!